Trial Search Results

This Phase 2, Double Blind, Placebo-controlled, Randomized Study is to Assess the Safety and Efficacy of Miricorilant in Obese Adult With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications.

This phase 2, double blind, placebo-controlled, randomized study is to assess the safety and efficacy of miricorilant in obese adult with schizophrenia treated with antipsychotic medications.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Corcept Therapeutics

Stanford Investigator(s):


  • Drug: Miricorilant
  • Drug: Miricorilant


Phase 2


Inclusion Criteria:

   - Have a diagnosis of schizophrenia or bipolar disorder

   - Are currently taking oral or injectable atypical antipsychotic medication (except
   clozapine) and must have documented weight gain while on these medications

   - Must be on a stable dose of medication for 1 month prior to screening

   - Are able to successfully complete placebo tablet swallow test

   - Have a BMI ≥30 kg/m2

Exclusion Criteria:

   - Have a history of a medical condition affecting body weight (e.g., poorly controlled
   hyper- or hypothyroidism; eating disorder such as anorexia, bulimia, or binge eating;
   or polycystic ovary syndrome).

   - Have poorly controlled diabetes mellitus

   - Have poorly controlled hypertension

   - Have a history of hypotension

   - Have a history of orthostatic hypotension

Ages Eligible for Study

18 Years - 65 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305